Legal experts say federal judges are significantly aligned after a first-of-its-kind appellate ruling backing drugmakers’ policies on the government’s 340B drug discount program, but there’s less consensus on whether other appeals courts will follow suit.

The U.S. Court of Appeals for the Third Circuit was the first appeals court to weigh in on a dispute over the program that requires manufacturers to deliver discounted drugs to certain hospitals that serve low-income patients. The panel sided with manufacturers who argued an Obamacare amendment doesn’t require they supply lower-priced medications to an unlimited number of contract pharmacies.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]